Fed Picks Warsh! This Weekly Signal Just Revealed the Next Fed Trade…

In Today’s Masters in Trading: Live LIVE: Fed Picks Warsh! This Weekly Signal Just Revealed the Next Fed Trade… The race to lead the Fed has a clear winner. And it’s likely to trigger one of the biggest shake-ups to the nation’s central bank in decades. Kevin Warsh, former Federal Reserve Governor, has been nominated by President Trump to lead the U.S. central bank — and markets are already reacting to what that implies. Disillusionment with the Fed catapulted Warsh to the lead. And now Warsh’s nomination confirms something I put on your radar a couple of weeks ago. His past career – and what we know about his current view on the Fed – show us he’s not afraid to shake up the status quo. Warsh has long argued that money in circulation and balance-sheet policy matter more than interest rates when it comes to inflation and asset prices. In other words, liquidity — not just the fed funds rate — is the dominant, regime-defining variable. A Fed under Warsh will likely continue the encouraging developments we’ve seen recently. The Fed is already transitioning away from outright balance-sheet contraction toward a more neutral liquidity stance — something we haven’t seen since 2019. The quantitative tightening program we saw take off last year was the most aggressive in decades. That pressure is easing. Which means the question for traders isn’t “What will rates do from here?” It’s “Is liquidity expanding or contracting?” To answer that consistently, I built a simple tool to track net liquidity simply and consistently by monitoring three inputs. The output? It flashes weekly liquidity impulse that show whether liquidity is expanding or contracting. Now, I want to make sure Masters in Trading members have the ability to leverage this tool as the Fed’s regime shift happens in real time. So join me for today’s episode of Masters in Trading LIVE at 11 AM EST , where I’ll show you the key moves I’m watching from the Fed – and how to access the simple tool I’ve built. ALL ACCESS MEMBERS ALERT: In today’s All Access, I’ll answer questions from viewers about our open positions. Don't have All Access? Call 1-800-784-0871 to learn more. Recommended Link Why 33% of your 401(k) is in just 7 stocks If you own an S&P 500 fund, one-third is concentrated in Apple, Microsoft, Google, Amazon, Meta, Tesla, and Nvidia. Louis Navellier’s system is flashing red for many of them. Your “diversified” portfolio isn’t diversified. Watch his urgent briefing on how to reposition. Got a Question? Be sure to join me live on YouTube and ask me anything. It’s a great way to connect directly with our trading community and make sure you’re getting the insights you need to help build a deeper understanding of the markets. Remember, the creative trader wins, Jonathan Rose Founder, Masters in Trading Who is Jonathan Rose? In 1997, Jonathan got his start as a floor trader at the Chicago Mercantile Exchange. He traded futures on the Nasdaq and S&P 500 during the dot-com boom and bust. In 2003, he became Director of Trading at a leading proprietary trading firm. His job was to manage the risk for the entire firm… with dozens of traders under his supervision. In 2010, the firm sold to a billion-dollar hedge fund. And Jonathan took a career break to train for the Wisconsin Ironman. After completing the 140-mile triathlon, in 2011, he took his trading career in a new direction. He became a market maker at the world’s largest at the Chicago Board Options Exchange. It’s the world's largest and most influential options exchange. But it wasn’t until 2015 that he found his true passion – teaching regular folks how to trade like the pros at Masters in Trading. Since then, he’s trained more than 100 professional traders and helped thousands of folks learn to trade options like pros. These folks not only get to learn the ropes with Jonathan. They can also follow his trade recommendations in real time. To learn more about joining Jonathan’s thriving community, and becoming the best trader you can be, visit here. 90-Day Trade Hall of Fame Company (Ticker) Portfolio Gain Duration Albemarle Corp. Advanced Notice 959% 31 days iShares Ethereum Trust ETF Advanced Notice 275% 26 days Alphatec Holdings Inc Earnings Advantage 213% 18 days Lyft Inc Advanced Notice 209% 13 days Canadian Solar Inc Divergence Trader 124% 9 days Note: These trades represent previously closed positions.

Manage your account We hope this timely investment research is valuable to you. As you know, the markets move fast and conditions change frequently. So please check the current issue for the most recent advice. Please note that we cannot be liable for any missed bulletins caused by individual filters. To ensure that you continue to receive this valuable part of your service please take a moment to add services@exct.mastersintrading.com to your address book. Unsubscribe to stop receiving daily video reminder emails. You can reach us at feedback@investorplace.com or by calling 1-800-219-8592.   InvestorPlace Media LLC 1125 N. Charles St, Baltimore, MD 21201 Copyright 2026 All rights reserved.

Gold’s Wild Correction and What It Says About Risk

Safe-haven swings are forcing a rethink of hedges and portfolio sizing.

Your Daily Market Alert Latest News Gold Climbs, Then Has a Massive Drop. What this Correction Tells Us About Market Psychology The precious metals market is experiencing one of its most dramatic corrections in recent memory, with gold retreating substantially from its peak and silver attempting... Read More Latest News These Low Cost Stocks Could Bolster Your Portfolio in 2026 The most compelling investment opportunities often hide in plain sight, trading at prices that make mainstream investors uncomfortable. When established companies... Read More Sponsored Elon's Greatest Invention... Hidden in South Memphis? Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon's greatest invention ever... Yes, even bigger than Tesla or SpaceX. Click here now because after February 1st, it could be too late. Privacy Policy / Disclosures Latest News Some High-Yield Dividend ETFs Are Having Their Moment... Here's Why Something interesting is happening in the markets right now. After three years of watching growth stocks and the Magnificent Seven dominate every conversation... Read More Sponsored Gold Headed Above $6,000 per Ounce in 2026? Here's How to Play It... With so many strange events happening across the economy (consumer confidence plummeting, credit-card delinquencies soaring, and more), it's no wonder the richest investors are loading up on gold. But what you might not realize is that there's a much better way to profit from rising gold prices - WITHOUT ever touching an ETF, mining stock, or even bullion. Get the full details here. Privacy Policy / Disclosures Latest News Bitcoin's Brutal Week Reveals Deeper Market Fragilities The cryptocurrency markets are getting hammered right now, and Bitcoin's latest decline tells us more about the current investment landscape than just digital asset... Read More Sponsored Trump Steps In As AI Stock Heats Up – Is Time Running Out? Trump's rare public defense of a small company has analysts talking. Tied to AI's backbone and triggering a proven White House signal, this stock could be on the verge of a major breakout. Act before the window closes. Access the Full Report Instantly! Privacy Policy / Disclosures Sponsored Legendary Wall Street Stockpicker Names #1 Stock of 2026 (Privacy Policy/Disclosures) See the Coin Crypto Billionaires Are Quietly Buying → (Privacy Policy/Disclosures) Elon Says Tesla's Next Move Could "Affect the Future of the World" (Privacy Policy/Disclosures) Advertising Disclosure: This email contains paid advertisements. This email is from our associates at Investment News Daily. Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc. Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below. Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below. Darwin Investor Network 2319 N Andrews Avenue, Fort Lauderdale, FL 33311 support@investingideasdaily.com | 1-800-496-9838 Investing Ideas Daily | Privacy Policy | Terms of Use Unsubscribe | View Online

Buy this $2 Gold Stock Before May 20, 2026

One small gold stock will be preparing to mine its first ounce of gold. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Dear reader,

January 2026…

One small gold stock just started to mine its first ounce of gold. 

I believe that once this news hits the markets, it will send this $2 gold stock soaring. 

That’s because right now, the company is pre-revenue. 

So, it’s invisible to the algos and AI programs that make up the bulk of daily trading. 

But now it started to generate gold - and cash - it will be like flicking a light switch once the Wall Street Automated Trading Systems(ATS) can see the numbers.

The world’s most powerful trading computers will bid up prices to match fair value.

And it all happens when the company’s first financial reports are posted in May 2026. 

Which means:

You need to own this company now - before the company’s initial production is made public. 

Click here to get the full briefing before it’s too late.

Best, 

Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio

 
 
 
 
 
 

---

More Reading from MarketBeat Media

Physical AI: The Next Industrial Revolution Is Finally Here

Submitted by Jeffrey Neal Johnson. Published: 1/30/2026.

What You Need to Know

• The integration of artificial intelligence into physical machines marks a new era in which digital brains can finally control mechanical bodies.
• Rockwell Automation secures its position as a sector leader by winning major contracts to power global electric vehicle manufacturing facilities.
• Serve Robotics expands its addressable market beyond food delivery by acquiring technology that automates high-value hospital logistics workflows.

For the past 24 months, the technology sector has been dominated by a single narrative: generative AI. Software platforms that can write code, compose poetry and generate images have captured both the public imagination and investor capital. As we move through early 2026, that narrative is shifting. The digital brain is maturing; investors are now looking for the mechanical body to do the heavy lifting.

This area—often called Physical AI—sits at the intersection of advanced algorithms and industrial hardware. The trend is more than a novelty; it responds to a structural economic need. The United States and other developed economies face persistent labor shortages: manufacturing plants, hospitals and other institutions cannot find enough machinists, nurses or support staff.

Central banks are lying to you about gold (Ad)

Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia's money and showed the world that assets can be seized. Now major nations want out. There's only one asset no one can freeze: gold.

Get the name and ticker of one stock positioned for this shift.

That reality is changing corporate spending. Companies are no longer automating just to cut costs; they are automating to sustain operations. They need machines that can navigate dynamic environments, make real-time decisions and work alongside humans. For the stock market, this creates a compelling barbell opportunity: investors can choose between massive, established infrastructure players that build factories, and agile, emerging disruptors addressing service labor shortages.

The Industrial Anchor: Rockwell Automation

Rockwell Automation (NYSE: ROK) is often labeled a legacy industrial name, but that underestimates the company's technological evolution. Rockwell makes the sensors, controllers and software that serve as the central nervous system for modern manufacturing. As factories race to become smart, they are increasingly relying on Rockwell's Connected Enterprise strategy.

The Edge AI Advantage

A key differentiator for Rockwell is its focus on edge AI. In a high-speed factory, a robot cannot tolerate the split-second delay of sending data to the cloud and waiting for a response. It needs to process information locally. Rockwell has integrated advanced AI chips directly into its controllers, allowing production lines to detect defects and adjust machinery in milliseconds—even without continuous internet connectivity.

The Lucid Motors Catalyst

In January 2026, Rockwell validated its order book by securing a major contract with Lucid Motors. Rockwell will provide the automation backbone for Lucid's new electric vehicle (EV) manufacturing facility in Saudi Arabia. That deal highlights two important points for investors:

• Sector Resilience: Even as consumer EV demand ebbs and flows, EV manufacturing continues to attract substantial capital investment.
• Vendor Validation: Lucid's selection of Rockwell confirms that for greenfield mega-projects, Rockwell remains a preferred automation partner.

The Money Matters

Rockwell's financials reflect a company returning to growth after an inventory correction.

• FY 2025 Performance: The company closed the fiscal year with adjusted earnings per share (EPS) of $10.53, up about 7% year over year.
• FY 2026 Guidance: Management is forecasting a return to double-digit growth, projecting EPS in the range of $11.00 to $12.11.
• The Dividend: For income-focused investors, Rockwell pays a quarterly dividend of $1.38 per share, providing a steady yield that can help cushion volatility while the industrial cycle improves.

The Emerging Disruptor: Serve Robotics

Where Rockwell dominates the controlled factory environment, Serve Robotics (NASDAQ: SERV) is tackling the chaotic, unpredictable world of public spaces. Serve is known for its four-wheeled autonomous delivery robots operating on city sidewalks. The company is in the execution phase of a major scale-up, planning to deploy a fleet of up to 2,000 robots with its commercial partner, Uber Eats.

Crucially, Serve has addressed one of the hardest challenges for a hardware startup: manufacturing at scale. By partnering with Magna International (NYSE: MGA), a global automotive supplier, Serve can produce robots with automotive-grade durability without building its own assembly lines.

The Pivot: Entering Healthcare

On Jan. 20, 2026, Serve's investment thesis expanded significantly when it announced the acquisition of Diligent Robotics, maker of the Moxi hospital robot. The move broadens Serve from a last-mile delivery company into a broader automation platform.

• High-Value Tasks: Delivering a burrito is low-margin; transporting lab samples or medication in a hospital is higher-value.
• Alleviating Burnout: Moxi robots fetch supplies for nurses. With nursing burnout at elevated levels, hospitals are willing to pay for technology that keeps clinicians at the bedside instead of running errands.
• Recurring Revenue: Healthcare contracts tend to be long-term and "sticky," offering Serve a more predictable revenue stream than consumer food delivery.

Growth and Risk

Serve Robotics is a different proposition than Rockwell: it is a high-growth, higher-risk investment.

• Revenue Growth: The company is reporting rapid top-line expansion, as shown in the third-quarter earnings report.
• Profitability: Serve is not yet profitable, operating at a net loss as it invests heavily in R&D and fleet expansion.
• Cash Runway: To mitigate that risk, Serve maintains a healthy balance sheet. With roughly $183 million in cash, the company has liquidity to fund operations and integrate Diligent Robotics through 2026.

Building a Balanced Automation Portfolio

The rise of Physical AI is not a single vertical but a broad industrial transformation. As the technology matures, smart machines will become standard corporate assets—alongside company vehicles and laptops.

For investors, Rockwell Automation and Serve Robotics offer complementary exposure to this theme. Rockwell provides the stability of an industrial incumbent, backed by dividends and a dominant position in factory automation. Serve offers the upside of a disruptor, aggressively expanding into new verticals such as healthcare, where automation is increasingly necessary.

Holding both gives investors coverage across the spectrum of the Physical AI revolution—from the robots that build our cars to the robots that assist our nurses. The era of the chatbot is evolving; the era of the robot has arrived.

 

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.
 
This email message is a paid sponsorship for Golden Portfolio, a third-party advertiser of The Early Bird and MarketBeat.
 
If you need help with your account, don't hesitate to email MarketBeat's South Dakota based support team at contact@marketbeat.com.
 
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
 
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States of America..

 

See Also: Volatility is back. Here's how the best are positioned (From Crypto 101 Media)

Don’t let others trade on this before you do

Timing is everything, and we're giving you a jumpstart. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe Good morning, Timing is everything, and we’re giving you a jumpstart. Now you can get The Early Bird’s “Stock of the Day” delivered by text before it lands in the newsletter. You’ll be first to see the pick, the story behind it, and both sides of the trade. Each morning, you'll receive: Actionable stock picks, hand-selected by MarketBeat's team of expert research analysts. Headlines and market insights for each selected ticker. A bull case and a bear case to help inform your next move. Timely updates and alerts so that you can capitalize quickly on each opportunity. Now you can move faster and trade smarter. Click Here to Receive The Early Bird's Stock of the Day Best regards, The Early Bird Team       Today's Exclusive News Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Reported by Jordan Chussler. Originally Published: 1/19/2026. Key Points With the FDA approval of GLP-1 agonists in pill form, the healthcare industry is looking to build on last year's momentum. Grand View Research forecasts the GLP-1 drug market to grow by a CAGR of nearly 19% through 2030. The Roundhill GLP-1 & Weight Loss ETF, which has gained 52% over the past year, provides a basket of leading companies involved in the manufacturing and sales of weight-loss drugs. After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.  In large part, that rebound was fueled by increasing demand for weight-loss drugs such as GLP-1 agonists and semaglutide treatments, including Ozempic, Wegovy, Zepbound, and Mounjaro.  The biggest scam in the history of gold markets is unwinding (Ad) There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It's like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis. Get the full story on this opportunity now. While the popularity of injectable treatments peaked in 2025, the recently FDA-approved pill form of weight-loss drugs could be an even bigger catalyst in 2026. For investors seeking exposure, a number of Big Pharma companies in this space could boost portfolios next year. But one exchange-traded fund (ETF)—the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM)—offers a one-stop option, holding a basket of leading companies involved in the manufacturing and sale of weight-loss drugs.  America’s Weight-Loss Fixation Is Driving Massive Growth  Industry consultancy Grand View Research forecasts the GLP-1 drug market to grow at a compound annual growth rate of 18.54% between 2024 and 2030, increasing global market value from $13.84 billion to $48.84 billion. North America has dominated the GLP-1 agonists market, accounting for nearly 76% of overall revenue.  That growth has already benefited shareholders of companies dominating the space, including Novo Nordisk (NYSE: NVO), maker of Ozempic and Wegovy, and Eli Lilly (NYSE: LLY), maker of Zepbound and Mounjaro.  While not as prominent historically in weight loss, Pfizer (NYSE: PFE) has recently increased its push in the category, signing a $2.1 billion licensing agreement in December 2025 to develop an early-stage weight-loss pill with a Chinese partner.  Pills, like injectables, are expected to be a major growth driver. On Eli Lilly's Q3 earnings call last fall, Dan Skovronsky, the company's chief scientific and medical officer and president of Lilly Immunology, stressed the role oral therapies will play going forward. Specifically, Skovronsky described a "goal to deliver efficacy similar to injectable GLP-1 monotherapy in an easy-to-use daily pill," and added that "we expect results from up to six phase III studies by the end of 2026." He also said he expects retatrutide to "deliver deeper and more rapid weight-loss than existing obesity medicines, even more than tirzepatide," the active ingredient in Mounjaro and Zepbound. That momentum has already produced significant customer gains for leading drugmakers. Novo Nordisk, for example, has reached 46 million customers, with CEO Mike Doustdar saying there are "around 3 million more people with our GLP-1 treatment compared to just 12 months ago." The All-in-One ETF for Weight-Loss Market Exposure  The Roundhill GLP-1 & Weight Loss ETF provides exposure to major players in the GLP-1 and semaglutide markets. The thematic fund gained nearly 52% over the past year and about 75% since its one-year low on April 8, 2025.  Much of that performance stems from the recent strength of three Big Pharma companies—Novo Nordisk, Eli Lilly, and Pfizer—which together account for almost 40% of the ETF's weighting, with NVO and LLY the two largest allocations. OZEM's fourth-largest holding, with a 4.41% weighting, is Viking Therapeutics (NASDAQ: VKTX), whose dual GLP-1/GIP agonist, VK2735, is in advanced clinical trials for obesity and metabolic disorders and is being developed in both injectable and oral formulations. Additionally, Amgen (NASDAQ: AMGN)—the ETF's ninth-largest holding with a 3.58% weighting—is developing MariTide, a weight-loss candidate designed for monthly or quarterly dosing rather than daily or weekly administration; it is currently in late-stage Phase 3 trials. Additionally, the Roundhill ETF holds AstraZeneca (NASDAQ: AZN) and Regeneron Pharmaceuticals (NASDAQ: REGN). AstraZeneca is awaiting FDA decisions on several oral, daily GLP-1 candidates, while Regeneron is exploring combination therapies that pair its muscle-preserving antibodies, trevogrumab and garetosmab, with GLP-1 drugs like Wegovy and Ozempic to enhance fat loss while preserving muscle mass.  What Wall Street Thinks About OZEM  The ETF carries a net expense ratio of 0.59% and receives an aggregate Moderate Buy rating. Average daily trading volume is modest, around 34,525 shares, but institutional buyers have been net buyers over the past year, with $7.18 million in inflows versus about $271,390 in outflows.  Current short interest is 6.3%—roughly 89,526 of the fund's 1.5 million shares outstanding. Of the 13 consensus ratings covering companies in its portfolio, 11 assign the ETF a Buy or Moderate Buy, while two assign it a Hold and none rate it a Sell.

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.   If you need assistance with your account, please feel free to email our South Dakota based support team at contact@marketbeat.com.   If you no longer wish to receive email from The Early Bird, you can unsubscribe.   © 2006-2026 MarketBeat Media, LLC. All rights protected. 345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103. United States..